Thyrotropin Alfa dosage in published studies and labels

These are the doses used for Thyrotropin Alfa in FDA labelling and published clinical studies, reported as each source states them, one row per regimen. They describe what was studied or approved for a specific population. They are not a recommendation, and none of them is a dose for any individual.

Research and educational reference only. This is not medical advice, and no figure on this page is a dosing recommendation.

Last checked against primary sources: November 7, 2026

Studied regimens and sources

Thyrotropin alfa has an FDA-approved human dosage as THYROGEN for people who have had thyroidectomy for well-differentiated thyroid cancer. The label regimen is two 0.9 mg intramuscular injections into the buttock 24 hours apart, used before serum thyroglobulin testing (with or without radioiodine imaging) or as an adjunct to radioiodine ablation of thyroid remnants.

FDA Approved

Dosage evidence summary for Thyrotropin Alfa
Human dosing established	Yes
Studied dose range	0.9 mg intramuscularly, two injections 24 hours apart
Route	Intramuscular
Frequency	Two injections 24 hours apart
Duration studied	One two-injection course per test or ablation
Evidence level	FDA Approved
Last reviewed	2026-11-07

Research-reported dosing

Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.

Research-reported dosing for Thyrotropin Alfa, one row per studied regimen
Study / context	Population	Dose	Route	Frequency	Duration	Outcome studied	Source
FDA label — THYROGEN, diagnostic thyroglobulin testingFDA-approved label · FDA prescribing information	Patients with well-differentiated thyroid cancer who have had thyroidectomy	0.9 mg, then a second 0.9 mg 24 hours later	Intramuscular (buttock); not intravenous	Two injections 24 hours apart	Serum thyroglobulin sampled 72 hours after the final injection; radioiodine for scanning given 24 hours after the second injection	Adjunctive diagnostic tool in thyroid cancer follow-up	THYROGEN (thyrotropin alfa) for injection — FDA prescribing information (Genzyme), DailyMed
FDA label — THYROGEN, adjunct to remnant ablationFDA-approved label · FDA prescribing information	Patients after near-total or total thyroidectomy for well-differentiated thyroid cancer, without evidence of distant metastases	0.9 mg, then a second 0.9 mg 24 hours later	Intramuscular (buttock); not intravenous	Two injections 24 hours apart	Oral radioiodine given 24 hours after the second injection	Radioiodine ablation of thyroid tissue remnants	THYROGEN (thyrotropin alfa) for injection — FDA prescribing information (Genzyme), DailyMed

Where sources disagree

The label's trials compare THYROGEN with thyroid hormone withdrawal. Its limitations of use say THYROGEN-stimulated thyroglobulin levels are generally lower than, and do not correlate with, levels after withdrawal, and that a risk of missing thyroid cancer remains even with radioiodine imaging.
The label warns of THYROGEN-induced hyperthyroidism, stroke in female patients, neurologic events in patients with central nervous system metastases, and sudden, painful enlargement of distant metastatic thyroid cancer.